Shire’s Board has notified Takeda that it would be “willing to recommend" the latter’s latest merger proposal to shareholders, which is now valued at £46 billion pounds. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/shire,_takeda_move_closer_to_merger_deal_1233173Astellas has filed its experimental Acute Myeloid Leukemia (AML) therapy gilteritinib with US regulators, seeking approval for its use to treat FLT3 mutation-positive (FLT3mut+) relapsed or refractory forms of the blood cancer. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/astellas_files_experimental_aml_therapy_1233254UCB and Amgen have brought their bone-boosting drug Evenity back to US regulators for review, following an initial rejection in July last year. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/ucb,_amgen_refile_osteoporosis_drug_evenity_1244387US regulators have rejected Lipocine’s Tlando, a testosterone replacement therapy for adult males with hypogonadism. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/testosterone_replacement_drug_rejected_by_fda_1235037Takeda has put forward a new proposed bid for Shire, increasing the cash portion of the deal. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/takeda_ups_its_offer_for_shire_1232830A UK-based life sciences group developing synthetic alternatives to antibodies has raised investment of £1.5 million to help advance its business. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/uk_synthetic_antibody_firm_raises_1.5m_1234808Swiss drugs giant Roche is rejoining the Association of the British Pharmaceutical Industry after cutting ties with the trade body seven years ago. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/roche_rejoins_apbi_1119375AstraZeneca has entered into a strategic joint venture with the Chinese Future Industry Investment Fund (FIIF) to form an equally-owned, stand-alone company in China. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/az_forms_new_company_in_china_1212680US biotech Acorda Therapeutics is discontinuing development of its experimental Parkinson’s disease therapy tozadenant on concerns over patient safety. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/acorda_drops_experimental_parkinsons_drug_1212108Central and North West London NHS Foundation Trust is intending to launch the first center that aims to treat internet addiction. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/nhs_trust_plans_first_internet_addiction_centre_1241789
